Related Experiment Videos
Prevention of contrast-induced bradycardia during coronary angiography
Insights
Prophylactic atropine sulfate effectively prevents dangerous heart pauses during coronary angiography. This study shows atropine is a safe and common method to avoid bradycardia in patients undergoing the procedure.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Coronary angiography can induce bradycardia, a slow heart rate.
- Contrast media used in angiography can cause significant cardiac events.
- Predicting and preventing these events is crucial for patient safety.
Purpose of the Study:
- To evaluate the safety and efficacy of atropine sulfate in preventing contrast-induced bradycardia.
- To assess the incidence of bradycardia and heart block during coronary angiography.
- To determine if prophylactic atropine affects other cardiac arrhythmias or angina.
Main Methods:
- A double-blind study involving 90 patients undergoing coronary angiography.
- Patients received either 0.6 mg of atropine sulfate or a placebo.
- The Sones technique was used for angiography, monitoring for ventricular pauses and arrhythmias.
Main Results:
- Prophylactic atropine significantly reduced ventricular pauses (6% vs. 49% in placebo).
- Atropine increased resting heart rate but did not cause other arrhythmias.
- Contrast-induced asystole is common and unpredictable, but preventable with atropine.
Conclusions:
- Prophylactic atropine sulfate is a safe and effective method to prevent contrast-induced bradycardia during coronary angiography.
- Atropine does not increase the risk of other arrhythmias or angina, even in patients with severe coronary disease.
- This intervention offers a reliable solution for a common complication of cardiac procedures.
Abstract:
A double-blind study of 90 patients undergoing coronary angiography was performed to determine the safety and efficacy of 0.6 mg atropine sulfate in preventing contrast-induced bradycardia. Coronary angiography performed using the Sones technique resulted in ventricular pauses of greater than 2 seconds in 3 of 49 patients (6%) who received prophylactic atropine and 20 of 41 patients (49%) receiving placebo. Though the pauses were usually due to atrial asystole, 26% of those with greater than 2 second pauses did so because of transient complete heart block. Prophylactic atropine did increase resting heart rate but did not cause other arrhythmias or increase the frequency of angina pectoris despite the presence of severe coronary disease. Our data indicate that contrast-induced asystole is very common, cannot be predicted by consideration of "precatheterization data," and can be prevented effectively and safely by use of prophylactic atropine sulfate.